HİLAL BALTA

Dr. HİLAL BALTA


Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
SÖSeda Er Özilhan
Seda Er Özilhan
SESafa Can Efil
Safa Can Efil
DÇDoğukan Çanakçı
Doğukan Çanakçı
YAYetkin Ağaçkıran
Yetkin Ağaçkıran
DDDidem Şener Dede
Didem Şener Dede
HDHayriye Tatlı Dogan
Hayriye Tatlı Dogan
Background: Lung cancer remains the leading cause of cancer-related deaths worldwide, with non-small cell lung carcinomas (NSCLCs) comprising the majority of cases. Among the common driver mutations, KRAS plays a critical role in guiding treatment strategies. This study evaluates the expression of programmed death-ligand 1 (PD-L1) and hypoxia-inducible factor 1-alpha (HIF-1α) in KRAS-mutant NSCLCs and investigates their associations with clinicopathological findings. Methods: A total of 85 cases with KRAS mutations were analyzed. Immunohistochemical staining for HIF-1α and PD-L1 was performed, and their relationships with mutation status and prognostic variables were assessed. Results: A significant correlation was identified between HIF-1α expression and PD-L1 expression in tumor cells. While the KRAS G12C mutation was not significantly associated with HIF-1α expression in tumor cells, it demonstrated a notable relationship with HIF-1α expression in the tumor microenvironment and PD-L1 expression. However, PD-L1 and HIF-1α expression did not significantly influence overall survival outcomes. Conclusions: Expression of PD-L1 was positively correlated with HIF-1α, which may provide evidence for a novel therapy targeting PD-L1 and HIF-1α in NSCLC. Further comprehensive studies are warranted to elucidate the prognostic implications of tumor–microenvironment and mutation interactions.

1 September 2022 in Black Sea Journal of Health Science
Verified
Journal Article
Closed access
HBHİLAL BALTA
HİLAL BALTA
ICIlknur Calik
Ilknur Calik
ŞDŞenay Erdoğan Durmuş
Şenay Erdoğan Durmuş
SÖSevilay Özmen
Sevilay Özmen
ABAhmet Erkan Bilici
Ahmet Erkan Bilici
Steatocystoma multiplex (SM) is a rare benign genetic disorder consisted of multiple cystic with little or no nail and hair involvement. Steatocystoma is a hamartomatous malformation of the pilosebaceous unit consisting of dermal cysts filled with a sebum-like material. To examine the patient characteristics, locations, presentations and histopathological features of SM in a group of patients. We analyzed 9 patients retrospectively that histopathologically diagnosed as SM. Demographic data collected from pathology reports. Patients’ mean age was 43.7 years (range: 15-69 years), with a male to female ratio of 7:2. The average diameter of the lesion at presentation was 13.2 mm (range: 2–30 mm), although 4 cases were less than or equal to 5 mm in size. The lesions located in neck, conjuctiva, face and frontal region. The most common clinical presentation was a painless skin lesion which was noticed incidentally. Histopathological examination of skin showed presence of cystic formation with sebaceous gland on its wall in the dermis and typical stratified squamous epithelium that showed wavy shaped stratum corneum, refractile and strong eosinophilic infiltrated in the cystic wall. SMs are benign lesions more frequent in male patients and especially located in head and neck region. These lesions may be misdiagnosed or underreported.

22 March 2023 in Journal of Contemporary Medicine
Verified
Journal Article
Open access
PDF file
HBHİLAL BALTA
HİLAL BALTA
NKNevin Kocaman
Nevin Kocaman
ÖÜÖzlem Üçer
Özlem Üçer
Purpose: The purpose of the present study was to examine the roles of new proteins DARS2, Reelin, and Encurin in the differentiation of Clear-Cell Renal Cell Carcinoma (RCC) and Papillary Renal Cell Carcinoma (RCC). Clear-cell RCC is the most common malignancy of the kidney, and papillary RCC is the second most common malignant malignancy in this respect. They are neoplasms and show similarity to each other, both histologically and morphologically, in some cases. Differential diagnosis is important because treatment approaches and prognoses are different. Although careful histopathological examination and specific immunohistochemical markers are important for diagnosis, there are no specific antibodies that can be used reliably and the search for biomarkers continues in this regard. Materials and Methods: A total of 30 Clear-Cell RCC and 30 Papillary RCC cases were included in the present study. Patients were identified retrospectively by reviewing the hospital database and pathological reports. Pathological data were obtained from hospital medical archives and pathology reports. Results: It was found that DARS2, Reelin, and Encurin proteins were significantly higher in papillary RCC when compared to clear-cell RCC. Conclusion: It was concluded that DARS2, Reelin, and Encurin proteins may be potential biomarkers for the differentiation of Papillary RCC and Clear-Cell RCC.

9 February 2023 in Journal of Surgery and Medicine
Verified
Journal Article
Open access
PDF file
HBHİLAL BALTA
HİLAL BALTA
NKNevin Kocaman
Nevin Kocaman
OUOzlem Ucer
Ozlem Ucer
Background/Aim: Chromophobe renal cell carcinoma (CRCC), eosinophilic variant clear cell RCC, and oncocytomas are renal neoplasms with eosinophilic cytoplasm, and their differential diagnosis is challenging despite significant advances in molecular pathology. Although many biomarkers have been identified for the differential diagnosis of these neoplasms, specific markers have not yet been reported. No studies were found in the literature on the relationship between these tumors and the new molecules DARS2, reelin, and enkurin. This paper aims to determine the roles of these proteins in renal neoplasms with eosinophilic cytoplasm. Methods: The study retrospectively analyzed 30 EC RCC, 30 CRCC, and 30 oncocytoma cases, evaluated among renal neoplasms with eosinophilic cytoplasm, independent of demographic characteristics, in the Fırat University Medical Pathology Laboratory between 2012 and 2022. The most representative samples of the tumor were selected for each group, and the expression of DARS2, reelin, and enkurin proteins was evaluated by the immunohistochemical method. Results: The histoscore of DARS2 expression was highest in EC RCC and least in CRCC. DARS2 was seen to differentiate CRCC from oncocytoma and EC RCC. The histoscore of reelin and enkurin protein expression was highest in oncocytoma and lowest in ECRCC. The difference between the groups was statistically significant (P<0.05). Conclusion: DARS2 can be a useful biomarker for differentiating CRCC from EC RCC and oncocytoma, and enkurin and reelin can differentiate among these three groups. '+st+' Pathology Histology Embryology Pathology Motzer RJ, Jonasch E, Agarwal N, et al. Kidney Cancer, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2017;15(6):804–34. DOI: https://doi.org/10.6004/jnccn.2017.0100 Lam JS, Klatte T, Kim HL, et al. Prognostic factors and selection for clinical studies of patients with kidney cancer. Crit Rev Oncol Hematol. 2008;65(3):235–62. DOI: https://doi.org/10.1016/j.critrevonc.2007.08.003 Eichelberg C, Junker K, Ljungberg B, Moch H. Diagnostic and prognostic molecular markers for renal cell carcinoma: a critical appraisal of the current state of research and clinical applicability. Eur Urol. 2009;55(4):851–63. DOI: https://doi.org/10.1016/j.eururo.2009.01.003 Grignon DJ, Che M. Clear cell renal cell carcinoma. Clin Lab Med. 2005;25(2):305–16. DOI: https://doi.org/10.1016/j.cll.2005.01.012 Moch H, Ohashi R. Chromophobe renal cell carcinoma: current and controversial issues. Pathology. 2021;53(1):101–8. DOI: https://doi.org/10.1016/j.pathol.2020.09.015 Kuroda N, Kanomata N, Yamaguchi T, Imamura, et al. Immunohistochemical application of S100A1 in renal oncocytoma, oncocytic papillary renal cell carcinoma, and two variants of chromophobe renal cell carcinoma. Med Mol Morphol. 2011;44(2):111–5. DOI: https://doi.org/10.1007/s00795-009-0461-z Akgul M, Williamson SR. Immunohistochemistry for the diagnosis of renal epithelial neoplasms. Semin Diagn Pathol. 2022;39(1):1–16. DOI: https://doi.org/10.1053/j.semdp.2021.11.001 Gasparre G, Romeo G, Rugolo M, Porcelli AM. Learning from oncocytic tumors: Why choose inefficient mitochondria? Biochim Biophys Acta. 2011;1807(6):633–42. DOI: https://doi.org/10.1016/j.bbabio.2010.08.006 Leibovich BC, Lohse CM, Crispen PL, et al. Histological subtype is an independent predictor of outcome for patients with renal cell carcinoma. J urol. 2010;183(4):1309–15. DOI: https://doi.org/10.1016/j.juro.2009.12.035 Gakis G, Kramer U, Schilling D, Kruck, et al. Small renal oncocytomas: differentiation with multiphase CT. Eur J Radiol. 2011;80(2):274–8. DOI: https://doi.org/10.1016/j.ejrad.2010.06.049 Zhang X, Dong W, Zhang J, et al. A Novel Mitochondrial-Related Nuclear Gene Signature Predicts Overall Survival of Lung Adenocarcinoma Patients. Front Cell Dev Biol. 2021;9:740487. DOI: https://doi.org/10.3389/fcell.2021.740487 Khialeeva E, Lane TF, Carpenter EM. Disruption of reelin signaling alters mammary gland morphogenesis. Development. 2011;138(4):767–76. DOI: https://doi.org/10.1242/dev.057588 Hou R, Liu X, Yang H, et al. Chemically synthesized cinobufagin suppresses nasopharyngeal carcinoma metastasis by inducing ENKUR to stabilize p53 expression. Cancer Lett. 2022;531:57–70. DOI: https://doi.org/10.1016/j.canlet.2022.01.025 Kocaman N, Artaş G. Can novel adipokines, asprosin and meteorin-like, be biomarkers for malignant mesothelioma? Biotech Histochem. 2020;95(3):171–5. DOI: https://doi.org/10.1080/10520295.2019.1656344 Pan CC, Chen PC, Chiang H. Overexpression of KIT (CD117) in chromophobe renal cell carcinoma and renal oncocytoma. Am J Clin Pathol. 2004;121(6):878–83. DOI: https://doi.org/10.1309/A7M2XTMJQK0KPQER Yu YC, Han JM, Kim S. Aminoacyl-tRNA synthetases and amino acid signaling. Biochim Biophys Acta Mol Cell Res. 2021;1868(1):118889. DOI: https://doi.org/10.1016/j.bbamcr.2020.118889 Van Berge L, Hamilton EM, Linnankivi T, et al. Leukoencephalopathy with brainstem and spinal cord involvement and lactate elevation: clinical and genetic characterization and target for therapy. Brain. 2014;137(4):1019–29. DOI: https://doi.org/10.1093/brain/awu026 Guo C, Shao T, Jiang X, et al. Comprehensive analysis of the functions and prognostic significance of RNA-binding proteins in bladder urothelial carcinoma. Am J Transl Res. 2020; 12(11):7160–73. DOI: https://doi.org/10.21203/rs.3.rs-44292/v1 Wang J, Zhao X, Wang Y, et al. circRNA-002178 act as a ceRNA to promote PDL1/PD1 expression in lung adenocarcinoma. Cell Death Dis. 2020;11(1):32. DOI: https://doi.org/10.1038/s41419-020-2230-9 Ucer O, Kocaman N. New candidates in the differential diagnosis of malignant mesothelioma from benign mesothelial hyperplasia and adenocarcinoma; DARS2 and suprabasin. Tissue & cell. 2022;79:101920. DOI: https://doi.org/10.1016/j.tice.2022.101920 Chen F, Wang Q, Zhou Y. The construction and validation of an RNA binding protein-related prognostic model for bladder cancer. BMC cancer. 2021;21(1):244. DOI: https://doi.org/10.1186/s12885-021-07930-5 Casuscelli J, Weinhold N, Gundem G, Wang Let al. Genomic landscape and evolution of metastatic chromophobe renal cell carcinoma. JCI insight. 2017;2(12):92688. DOI: https://doi.org/10.1172/jci.insight.92688 Gabriella DA. Reelin in the Years: Controlling Neuronal Migration and Maturation in the Mammalian Brain Hunting. Neurosci. 2014;2014:1–19. DOI: https://doi.org/10.1155/2014/597395 Khialeeva E, Carpenter EM. Non-neuronal roles for the reelin signaling pathway. Dev Dyn. 2017;246(4):217–26. DOI: https://doi.org/10.1002/dvdy.24462 Stein T, Cosimo E, Yu X, et al. Loss of reelin expression in breast cancer is epigenetically controlled and associated with poor prognosis. Am J Pathol. 2010;177(5):2323–33. DOI: https://doi.org/10.2353/ajpath.2010.100209 Sutton KA, Jungnickel MK, Wang Y, et al. Enkurin is a novel calmodulin and TRPC channel binding protein in sperm. Dev Biol. 2004;274(2):426–35. DOI: https://doi.org/10.1016/j.ydbio.2004.07.031 Ma Q, Lu Y, Gu Y. ENKUR Is Involved in the Regulation of Cellular Biology in Colorectal Cancer Cells via PI3K/Akt Signaling Pathway. Technol Cancer Res Treat. 2019;18:1533033819841433. DOI: https://doi.org/10.1177/1533033819841433 Ma Q, Lu Y, Lin J, et al. ENKUR acts as a tumor suppressor in lung adenocarcinoma cells through PI3K/Akt and MAPK/ERK signaling pathways. J Cancer. 2019;10(17):3975–84. DOI: https://doi.org/10.7150/jca.30021 Song T, Zhou P, Sun C, et al. Enkurin domain containing 1 (ENKD1) regulates the proliferation, migration and invasion of non-small cell lung cancer cells. Asia Pac J Clin Oncol. 2022;18(2):39–45. DOI: https://doi.org/10.1111/ajco.13550 Copyright (c) 2023 Hilal Balta, Nevin Kocaman, Ozlem Ucer This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

1 January 2016 in Journal of Dr Behcet Uz Children s Hospital
Verified
Journal Article
Open access
ŞDŞenay Erdoğan Durmuş
Şenay Erdoğan Durmuş
HBHİLAL BALTA
HİLAL BALTA
SÖSevilay Akalp Özmen
Sevilay Akalp Özmen
AKAli Kurt
Ali Kurt
ICIlknur Calik
Ilknur Calik
FEFazlı Erdoğan
Fazlı Erdoğan

15 October 2025 in Journal of Turkish Society of Obstetric and Gynecology
Verified
Journal Article
Open access
PDF file
AŞAhmet Şenocak
Ahmet Şenocak
ŞYŞeyda Yavuzkır
Şeyda Yavuzkır
RARemzi Atılgan
Remzi Atılgan
NYNurdan Yurt
Nurdan Yurt
HBHİLAL BALTA
HİLAL BALTA
BCBunyamin Cim
Bunyamin Cim
Comparison of asprosin immunoreactivity in endometrial hyperplasia and grade-1 endometrial adenocarcinoma: A retrospective case-control study - Turkish Journal of Obstetrics and Gynecology